Market Currents
Jefferies is out with some cautious comments on Arena Pharmaceuticals (+4.4%) this morning,...
-
Monday, May 7, 2012, 11:48 AM ETJefferies is out with some cautious comments on Arena Pharmaceuticals (+4.4%) this morning, saying the shares haven't priced in the prospects for a delay in the rollout of its obesity drug Lorqesssays. The firm reiterates an Underperform rating on the stock with a $1 price target.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
